NICE requests more information from AstraZeneca on Lynparza

6 August 2015

The UK’s National Institute for health and Care Excellence (NICE) has opened a second consultation on preliminary draft guidance on Lynparza (olaparib) from AstraZeneca (LSE: AZN), asking the company for more information.

It is being considered as a maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer, and the drug is specifically for cancers in those who have tested positive for the BRCA1 or BRCA2 mutations, whose disease has responded to platinum-based chemotherapy.

The independent Appraisal Committee which developed the draft guidance is asking the company to provide a “robust estimate” of the cost-effectiveness of olaparib for the subgroup of patients with relapsed disease, who have had three or more courses of platinum-based chemotherapy. The information requested includes the cost of somatic testing, taking into account the committee’s concerns about its previous models, and full details of the data supporting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK